Clinical Trial Update: A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update on the interchangeability of ABP 654 for moderate to severe plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• ABP 654 (adalimumab biosimilar)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2024-01-11